

Biocompatibility Evaluation

| Product Name: | Nerve and Muscle Stimulator |
|--------------------------|--|
| Product Model | XFT-2003EA |
| Document No.: | ENNE-2003EA-147 |
| Version: | С |
| Document Type | Development Document |
| Confidentiality Level | Confidential |
| Project Code | RD48 |
| Printed Color | ⊠ Black □ Colour |
| Issue Dept. | □ R&D Dept. □ Quality & Regulatory Dept. □ Production Management Dept. |
| | ☐ Marketing Center ☐ QC Dept. ☐ Purchasing Dept. ☐ Engineering |
| | Dept. |

| Prepared by: | \$10 | Date: 7010. 7.28 |
|--------------|--------|------------------|
| Reviewed by: | Stafe | Date: 200. 7.28 |
| Approved by | 2 gark | Date: 27.78 |

受



| Related Documents | | | | |
|-------------------|---|------------------------|--|--|
| Document No. | Document Name | Version | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | 800 | | | |
| | 70F-AB500 | 5-391 3 - 1 2,001 1000 | | |
| - | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Dr. C | | | | |
| | ~ | | | |
| Le Cove C | | | | |
| \ c:\\. | 101100 | 100 100 | | |
| | | | | |
| | | | | |
| | | | | |



Revision Record

| Version | Description of the Revision | Revised by | Effective Date |
|---------|-----------------------------|------------|----------------|
| С | Initial issued | Li Fei | 2020. 7. 28 |
| | | | |
| | | | |
| | 34 % 34 | | |
| | in the diginal | | |
| | | | |
| | | | |
| | | | |
| | | | No. |
| | | | ,ac |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |



1 The product name and model

Trade name: Hand Rehab System

Product name: Nerve and Muscle Stimulator

Model: XFT-2003EA

2 The purpose of evaluation

Nerve and Muscle Stimulator (Model: XFT-2003EA) is the final product which need perform as intended and be safe for human use, especially including a biological evaluation according to FDA guidance- Use of International Standard ISO 10993-1, "Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process.

3 Evaluation of medical device

- 3.1 Materials/components in contact with the human body
 - 3.1.1 Illustration of accessible components





3.1.2 List of patient contact components

| Model# | Components | Patient contact material | Body Contact Location | Contact duration |
|------------|-----------------------------|--|---|---------------------|
| XFT-2003EA | Top cover | ABS920 | Indirect contact, patient hand may contact it during operation | More than 30days |
| | Bottom cover | PC+SUS316 | Indirect contact, patient hand will contact it during operation | More than 30days |
| | Metal electrode | SUS316 | Direct contact, patient hand will contact it during operation | More than 30days |
| | Wristband | ABS920+TPE(534 U)+SUS316 | Direct contact, patient hand will contact it during operation | More than 30days |
| | Hook & Loop (magic tape) | Imported nylon non-scratch 6210 Velcro, Imported nylon non-scratch 6210 Velcro | Indirect contact, patient hand may contact it during fasten the cuff. | More than 30days |
| | Display panel | PC | Indirect contact, patient hand will contact it during operation | More than 30days |

Note: The above materials are very common in daily life, these materials have the characteristic of has a high performance due to its high resistance to mechanical damage and protection from environmental factors. So, they have been widely used an applied in the medical industry recent years.

3.2 According to the description of section 3.1.1 and 3.1.2 in this document, the device can be considered as a surface device and contact with the intact skin of the body, the contact duration is less than 24 hours. Therefore, the device is categorized as "A" in according to Table A.1 of FDA guidance- Use of International Standard ISO 10993-1, "Biological evaluation of medical devices-Part 1: Evaluation and testing within a risk management process. The risk of adverse reaction such as in vitro cytotoxicity, skin irritation and skin sensitization should be considered.



Table A.1: Biocompatibility Evaluation Endpoints

| Medical | Medical device categorization by | | | Biological effect | | | | | | | | | | | |
|-----------------|----------------------------------|--|--------------|-------------------|---|-------------------------|--------------------------------|------------------------------|--------------|--------------|-------------------|------------------|-----------------|--------------------------------------|--------------|
| Nature of Boo | | Contact Duration A − limited (≤24 h) B − prolonged (>24 h to 30 d) C − permanent (> 30 d) | Cytotoxicity | Sensitization | Irritation or Intracutaneous Reactivity | Acute Systemic Toxicity | Material-Mediated Pyrogenicity | Subacute/Subchronic Toxicity | Genotoxicity | Implantation | Hemocompatibility | Chronic Toxicity | Carcinogenicity | Reproductive/Developmental Toxicity# | Degradation@ |
| a demonstration | | A | X | X | X | | | | | | | | 13 | | |
| | Intact skin | В | X | X | X | | | | | | | | | | - |
| | | С | X | X | X | | | | | | | | | | |
| | ice Mucosal | A | X | X | X | | | | | | | | | | |
| Surface device | | В | X | X | X | 0 | 0 | 0 | | 0 | | | | | |
| | membrane | С | X | X | X | 0 | 0 | X | X | 0 | | 0 | | | |
| | Breached or | A | X | X | X | 0 | 0 | | | 5 | | | | | |
| | compromised | В | X | X | X | 0 | 0 | 0 | | 0 | | | | | |
| | surface | С | X | X | X | 0 | 0 | X | X | 0 | | 0 | 0 | | |
| External | Diand mati- | A | X | X | X | X | 0 | | | | X | | | | ļ |
| communicating | Blood path, indirect | В | X | X | X | X | 0 | 0 | | | X | | | | <u> </u> |
| device | mulicu | C | X | X | О | X | 0 | X | X | 0 | X | 0 | 0 | | |



3.3 Evaluation endpoints for consideration

| Model | Components | Material | Corresponding Bio-c | io-compatibility Test | | | |
|-----------|-----------------------------|--|--|--|--|--|--|
| | | | In Vitro Cytotoxicity | Skin | Skin Irritation | | |
| | | | | Sensitization | 2, | | |
| XFT-2003E | Top cover | ABS920 | | | | | |
| A | Bottom cover | PC+SUS316 | | | | | |
| | Metal electrode | SUS316 | | ISO10993-10: | ISO10993-10: | | |
| | Wrist band | ABS920+TPE(534 | ISO10993-5: 2009 | Biological | Biological | | |
| | | U)+SUS316 | Biological | evaluation of | evaluation of | | |
| | Hook & Loop (magic tape) | Imported nylon non-scratch 6210 Velcro, Imported nylon non-scratch 6210 Velcro | evaluation of medical devices -Part 5: Tests for in vitro cytotoxicity | medical devices -Part 10: Tests for irritation and delayed-type hypersensitivity | medical devices -Part 10: Tests for irritation and delayed-type hypersensitivity | | |
| | Display panel | PC | | | | | |

4 Biological Safety Testing Results

| Model | Test Item | Test Report Number | Test Result |
|------------|-----------------------|--------------------------------------|-------------------------------|
| XFT-2003EA | In Vitro Cytotoxicity | SDWH-M201900697-1 (E) | The result showed that the |
| | ** | (007_ In Vitro Cytotoxicity Test) | test article has no potential |
| | | | toxicity |
| | Skin Sensitization | SDWH-M201900697-3 (E) | The results showed that the |
| | | (007_ Skin Sensitization Test Using | test article has no |
| | | Sesame Oil Extract); | significant evidence of |
| | **, | SDWH-M201900697-2 (E) | causing skin sensitization |
| | | (007_ Skin Sensitization Test Using | |
| * | | 0.9% Sodium Chloride Injection | |
| | | Extract) | |
| | Skin Irritation | SDWH-M201900697-5 (E) Amd01(E) | The test results showed |
| | | (007_Skin Irritation Test Using | that the response of the test |
| | | Sesame Oil Extract); | article extract was |
| | | SDWH-M201900697-4 (E) | categorized as negligible |
| | | (007_Skin Irritation Test Using 0.9% | under the test condition |
| | | Sodium Chloride Injection Extract) | |

5 Conclusion

The biocompatibility test result shows that the materials which used for the device did not have any potential toxicity, skin sensitization and skin irritation. In







conclusion, the biocompatibility of the Nerve and Muscle Stimulator (Model: XFT-2003EA,) conforms to the intended use and regulation requirement.